目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Condition
1.1.2. Linker
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2

Chapter 2. Executive Summary
2.1. Market Outlook

Chapter 3. Antibody Drug Conjugates Contract Manufacturing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising incidence of cancer
3.2.1.2. High cost of manufacturing ADC and challenges associated with manufacturing contributing to the demand for contract manufacturing
3.2.1.3. Increasing R&D activities on ADCs
3.2.2. Market restraint analysis
3.2.2.1. Quality issues while outsourcing
3.2.2.2. Limited outsourcing opted by big biopharma Companies
3.3. Antibody Drug Conjugates Contract Manufacturing Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTLE Analysis
3.3.3. Major Deals & Strategic Alliances Analysis
3.3.3.1. Mergers and acquisition
3.3.3.2. Expansions
3.3.3.3. Agreements and collaborations
3.3.3.4. Product and service launches
3.4. Covid-19 Impact and Reformation Strategy

Chapter 4. Antibody Drug Conjugates Contract Manufacturing Market: Condition Estimates & Trend Analysis
4.1. Definitions and Scope
4.2. Antibody Drug Conjugates Contract Manufacturing Market Share, 2022 & 2030
4.3. Myeloma
4.3.1. Myeloma market estimates and forecast 2018 to 2030 (USD Million)
4.4. Lymphoma
4.4.1. Lymphoma market estimates and forecast 2018 to 2030 (USD Million)
4.5. Breast Cancer
4.5.1. Breast Cancer market estimates and forecast 2018 to 2030 (USD Million)
4.6. Others
4.6.1. Others market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Antibody Drug Conjugates Contract Manufacturing Market: Linker Estimates & Trend Analysis
5.1. Definitions and Scope
5.2. Antibody Drug Conjugates Contract Manufacturing Market Share, 2022 & 2030
5.3. Cleavable linker
5.3.1. Cleavable linker market estimates and forecast 2018 to 2030 (USD Million)
5.4. Non-cleavable linker
5.4.1. Non-cleavable linker market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Antibody Drug Conjugates Contract Manufacturing Market: Regional Estimates & Trend Analysis
6.1. Regional market share analysis, 2022 & 2030
6.2. North America
6.2.1. U.S.
6.2.1.1. U.S. market estimates and forecast, 2018 - 2030
6.2.2. Canada
6.2.2.1. Canada market estimates and forecast, 2018 - 2030
6.3. Europe
6.3.1. U.K.
6.3.1.1. U.K. market estimates and forecast, 2018 - 2030
6.3.2. Germany
6.3.2.1. Germany market estimates and forecast, 2018 - 2030
6.3.3. France
6.3.3.1. France market estimates and forecast, 2018 - 2030
6.3.4. Italy
6.3.4.1. Italy market estimates and forecast, 2018 - 2030
6.3.5. Spain
6.3.5.1. Spain market estimates and forecast, 2018 - 2030
6.3.6. Denmark
6.3.6.1. Denmark market estimates and forecast, 2018 - 2030
6.3.7. Sweden
6.3.7.1. Sweden market estimates and forecast, 2018 - 2030
6.3.8. Norway
6.3.8.1. Norway market estimates and forecast, 2018 - 2030
6.4. Asia Pacific
6.4.1. Japan
6.4.1.1. Japan market estimates and forecast, 2018 - 2030
6.4.2. China
6.4.2.1. China market estimates and forecast, 2018 - 2030
6.4.3. India
6.4.3.1. India market estimates and forecast, 2018 - 2030
6.4.4. Australia
6.4.4.1. Australia market estimates and forecast, 2018 - 2030
6.4.5. Thailand
6.4.5.1. Thailand market estimates and forecast, 2018 - 2030
6.4.6. South Korea
6.4.6.1. South Korea market estimates and forecast, 2018 - 2030
6.5. Latin America
6.5.1. Brazil
6.5.1.1. Brazil market estimates and forecast, 2018 - 2030
6.5.2. Mexico
6.5.2.1. Mexico market estimates and forecast, 2018 - 2030
6.5.3. Argentina
6.5.3.1. Argentina market estimates and forecast, 2018 - 2030
6.6. MEA
6.6.1. South Africa
6.6.1.1. South Africa market estimates and forecast, 2018 - 2030
6.6.2. Saudi Arabia
6.6.2.1. Saudi Arabia market estimates and forecast, 2018 - 2030
6.6.3. UAE
6.6.3.1. UAE market estimates and forecast, 2018 - 2030
6.6.4. Kuwait
6.6.4.1. Kuwait market estimates and forecast, 2018 - 2030

Chapter 7. Competitive Analysis
7.1. Recent Developments & Impact Analysis, By Key Market Participant
7.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
7.3. Participant Categorization

Chapter 8. Competitive Landscape
8.1. Company Profiles
8.1.1. Recipharm AB
8.1.1.1. Company overview
8.1.1.2. Financial performance
8.1.1.3. Service benchmarking
8.1.1.4. Strategic initiatives
8.1.2. Samsung Biologics
8.1.2.1. Company overview
8.1.2.2. Financial performance
8.1.2.3. Service benchmarking
8.1.2.4. Strategic initiatives
8.1.3. Lonza
8.1.3.1. Company overview
8.1.3.2. Financial performance
8.1.3.3. Service benchmarking
8.1.3.4. Strategic initiatives
8.1.4. Piramal Group (Piramal Pharma Solutions)
8.1.4.1. Company overview
8.1.4.2. Financial performance
8.1.4.3. Service benchmarking
8.1.4.4. Strategic initiatives
8.1.5. Sterling
8.1.5.1. Company overview
8.1.5.2. Financial performance
8.1.5.3. Service benchmarking
8.1.5.4. Strategic initiatives
8.1.6. Sartorius AG
8.1.6.1. Company overview
8.1.6.2. Financial performance
8.1.6.3. Service benchmarking
8.1.6.4. Strategic initiatives
8.1.7. Catalent, Inc
8.1.7.1. Company overview
8.1.7.2. Financial performance
8.1.7.3. Service benchmarking
8.1.7.4. Strategic initiatives
8.1.8. Wuxi Biologics
8.1.8.1. Company overview
8.1.8.2. Financial performance
8.1.8.3. Service benchmarking
8.1.8.4. Strategic initiatives
8.1.9. AbbVie, Inc. (AbbVie Contract Manufacturing)
8.1.9.1. Company overview
8.1.9.2. Financial performance
8.1.9.3. Service benchmarking
8.1.9.4. Strategic initiatives
8.1.10. Merck KGaA
8.1.10.1. Company overview
8.1.10.2. Financial performance
8.1.10.3. Service benchmarking
8.1.10.4. Strategic initiatives

List of Tables
Table 1 List of secondary sources
Table 2 List of Abbreviations

List of Figures
Fig 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Volume Price Analysis
Fig. 10 Antibody drug conjugates contract manufacturing market snapshot (2022)
Fig. 11 Antibody drug conjugates contract manufacturing market segmentation
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Porter’s five forces analysis
Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 17 Antibody drug conjugates contract manufacturing market condition outlook: Segment dashboard
Fig. 18 Antibody drug conjugates contract manufacturing market: Condition movement analysis
Fig. 19 Myeloma market (USD Million)
Fig. 20 Lymphoma market (USD Million)
Fig. 21 Breast Cancer market (USD Million)
Fig. 22 Others market (USD Million)
Fig. 23 Antibody drug conjugates contract manufacturing market linker outlook: Segment dashboard
Fig. 24 Antibody drug conjugates contract manufacturing market: Linker movement analysis
Fig. 25 Cleavable Linker market (USD Million)
Fig. 26 Non-Clevable Linker market (USD Million)
Fig. 27 Regional market: Key takeaways
Fig. 28 Regional outlook, 2022 & 2030
Fig. 29 North America market, 2018 - 2030 (USD Million)
Fig. 30 U.S. market, 2018 - 2030 (USD Million)
Fig. 31 Canada Market, , 2018 -2030 (USD Million)
Fig. 32 Europe Market, , 2018 -2030 (USD Million)
Fig. 33 U.K. Market, , 2018 -2030 (USD Million)
Fig. 34 Germany Market, , 2018 -2030 (USD Million)
Fig. 35 France Market, , 2018 -2030 (USD Million)
Fig. 36 Italy Market, 2018 -2030 (USD Million)
Fig. 37 SpainMarket, 2018 -2030 (USD Million)
Fig. 38 Denmark Market, 2018 -2030 (USD Million)
Fig. 39 SwedenMarket, 2018 -2030 (USD Million)
Fig. 40 Norway Market, By Service, 2018 -2030 (USD Million)
Fig. 41 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 42 China market, 2018 - 2030 (USD Million)
Fig. 43 India market, 2018 - 2030 (USD Million)
Fig. 44 Japan market, 2018 - 2030 (USD Million)
Fig. 45 Australia market, 2018 - 2030 (USD Million)
Fig. 46 Thailand market, 2018 - 2030 (USD Million)
Fig. 47 South Korea market, 2018 - 2030 (USD Million)
Fig. 48 Latin America market, 2018 - 2030 (USD Million)
Fig. 49 Brazil market, 2018 - 2030 (USD Million)
Fig. 50 Mexico market, 2018 - 2030 (USD Million)
Fig. 51 Argentina market, 2018 - 2030 (USD Million)
Fig. 52 MEA market, 2018 - 2030 (USD Million)
Fig. 53 South Africa market, 2018 - 2030 (USD Million)
Fig. 54 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 55 UAE market, 2018 - 2030 (USD Million)
Fig. 56 Kuwait market, 2018 - 2030 (USD Million)